Pages that link to "Q60915531"

The following pages link to Emma C Morris (Q60915531):

Displaying 48 items.

• Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses (Q34617770) (← links)
• Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning (Q34975409) (← links)
• Reduced intensity allogeneic stem cell transplantation for low grade non-Hodgkin's lymphoma. (Q36031884) (← links)
• Monoclonal T-cell receptors: new reagents for cancer therapy. (Q36885379) (← links)
• Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy (Q37216330) (← links)
• Challenges in T cell receptor gene therapy. (Q38011650) (← links)
• Immunotherapy with gene-modified T cells: limiting side effects provides new challenges. (Q38117268) (← links)
• Autologous stem cell transplantation outcomes in elderly patients with B cell Non-Hodgkin Lymphoma. (Q38539561) (← links)
• Cancer gene therapy with T cell receptors and chimeric antigen receptors (Q38581520) (← links)
• Optimizing T-cell receptor gene therapy for hematologic malignancies. (Q38840466) (← links)
• Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination (Q39568612) (← links)
• Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen (Q39747188) (← links)
• Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma (Q40020440) (← links)
• X-linked Inhibitor of Apoptosis Complicated by Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) and Granulomatous Hepatitis (Q40635508) (← links)
• Murine serpin 2A is a redox-sensitive intracellular protein. (Q40685055) (← links)
• T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma (Q42981942) (← links)
• HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning (Q43108048) (← links)
• Human MHC Class I-restricted high avidity CD4+ T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo. (Q43238571) (← links)
• Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma (Q43889132) (← links)
• Allogeneic hematopoietic stem cell transplantation and norovirus gastroenteritis: a previously unrecognized cause of morbidity. (Q44703488) (← links)
• Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation (Q45159702) (← links)
• Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure (Q45330725) (← links)
• A response-adjusted PET-based transplantation strategy in primary resistant and relapsed Hodgkin Lymphoma. (Q45396691) (← links)
• Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult (Q45869832) (← links)
• Ex Vivo PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients. (Q45941281) (← links)
• Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. (Q45968368) (← links)
• Adenoviremia has limited clinical impact in the majority of patients following alemtuzumab-based allogeneic stem cell transplantation in adults. (Q47246838) (← links)
• Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. (Q47426162) (← links)
• Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency. (Q49568332) (← links)
• Editing gene engineering to enhance function (Q49953512) (← links)
• Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma. (Q52983524) (← links)
• Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia (Q56461161) (← links)
• Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma (Q61053485) (← links)
• Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity (Q61651657) (← links)
• Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation (Q63440155) (← links)
• Prognostic factors and outcome for children after second central nervous system relapse of acute lymphoblastic leukaemia (Q73072424) (← links)
• Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications (Q73094439) (← links)
• Reversal of severe cholestasis caused by chronic graft-versus-host disease with the MARS liver-support device (Q73459895) (← links)
• Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimen (Q74305897) (← links)
• Allogeneic transplantation for hepatosplenic alphabeta T-cell lymphoma (Q81547172) (← links)
• Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure (Q82972291) (← links)
• Framework engineering to produce dominant T cell receptors with enhanced antigen-specific function (Q90425510) (← links)
• Anti-Müllerian hormone and Inhibin B after stem cell transplant in childhood: a comparison of myeloablative, reduced intensity and treosulfan-based chemotherapy regimens (Q90776334) (← links)
• Lentiviral gene therapy for X-linked chronic granulomatous disease (Q92979235) (← links)
• Correction: Anti-Müllerian hormone and Inhibin B after stem cell transplant in childhood: a comparison of myeloablative, reduced intensity and treosulfan-based chemotherapy regimens (Q93217167) (← links)
• Synonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiency (Q96576905) (← links)
• Engineered T cells Flt around their targets (Q97540371) (← links)
• Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome (Q112302867) (← links)